Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prakash Mistry

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|March 5, 2004
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistanceShouming Wang, Adrian Folkes, Irina Chuckowree, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 2008
4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinaseRikki Alexander, Ahrani Balasundaram, Mark Batchelor, et al.
Journal of Medicinal Chemistry|January 25, 2002
Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agentsNigel Vicker, Luke Burgess, Irina S Chuckowree, et al.
Journal of Medicinal Chemistry|March 5, 2004
Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistanceShouming Wang, Nan Chi Wan, John Harrison, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|March 5, 2004
Studies on pyrrolopyrimidines as selective inhibitors of multidrug-resistance-associated protein in multidrug resistanceShouming Wang, Adrian Folkes, Irina Chuckowree, et al.
Bioorganic & Medicinal Chemistry Letters|July 16, 2008
4-(1,3-Thiazol-2-yl)morpholine derivatives as inhibitors of phosphoinositide 3-kinaseRikki Alexander, Ahrani Balasundaram, Mark Batchelor, et al.
Journal of Medicinal Chemistry|January 25, 2002
Novel angular benzophenazines: dual topoisomerase I and topoisomerase II inhibitors as potential anticancer agentsNigel Vicker, Luke Burgess, Irina S Chuckowree, et al.
Journal of Medicinal Chemistry|March 5, 2004
Design and synthesis of new templates derived from pyrrolopyrimidine as selective multidrug-resistance-associated protein inhibitors in multidrug resistanceShouming Wang, Nan Chi Wan, John Harrison, et al.
Journal of Medicinal Chemistry|March 30, 2022
Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced MalignanciesYing Huang, Martin Sendzik, Jeff Zhang, et al.
Pageof 2